Synonyms: Aerumab 11 | Aerumab™ | AR-101 | KBPA101
Compound class:
Antibody
Comment: Panobacumab is a fully human IgM kappa monoclonal antibody directed against the O-polysaccharide component of surface lipopolysaccharide (LPS) of serotype O11 Pseudomonas aeruginosa [1]. It is under clinical development as an adjunctive immunotherapy for the treatment of nosocomial pneumonia caused by O11 serotype P. aeruginosa.
Annotated peptide sequences for this monoclonal antibody are available from its IMGT/mAb-DB record. |
Classification ![]() |
|
Compound class | Antibody |
International Nonproprietary Names ![]() |
|
INN number | INN |
8888 | panobacumab |
Synonyms ![]() |
Aerumab 11 | Aerumab™ | AR-101 | KBPA101 |
Database Links ![]() |
|
Specialist databases | |
Antibiotic DB
![]() |
AR-101 |
IMGT/mAb-DB | 243 |
Other databases | |
CAS Registry No. | 885053-97-4 (source: Scifinder) |
ChEMBL Ligand | CHEMBL1743055 |
DrugBank Ligand | DB15342 |
GtoPdb PubChem SID | 496703347 |
Search PubMed clinical trials | panobacumab |
Search PubMed titles | panobacumab |
Search PubMed titles/abstracts | panobacumab |